首页> 外文期刊>Science China Life Sciences >Ex vivo expansion of hematopoietic stem cells
【24h】

Ex vivo expansion of hematopoietic stem cells

机译:造血干细胞的体外扩增

获取原文
           

摘要

Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing. Keywords ex vivo expansion hematopoietic stem cells niche signal transduction cord blood transplantation SCID-repopulating cell genome editing CRISPR/Cas9.
机译:造血干细胞(HSC)的离体扩增将在多个方面有益于临床应用,以提高患者的生存率,将脐带血干细胞用于成人应用,并在基因操作后选择性繁殖干细胞。在这篇综述中,我们总结并讨论了小鼠和人类HSCs培养系统的最新进展,包括基质/ HSC共培养,连续灌注和分批补料培养,以及外源性配体,膜转运转录因子,补体成分的补充,蛋白质修饰酶,代谢产物或小分子化学物质。一些扩展系统已经在临床试验中进行了测试。原始和功能性人类HSC的离体扩增的最佳条件仍在开发中。对HSC细胞命运决定机制和HSC培养特性的更好理解将指导开发克服困难的新策略。将来,开发具有增强自我更新,阻断分化和改善归巢性的药物的联合治疗方案至关重要。应采用在收集和加工过程中提高产量和降低成本的方法。为离体扩增HSC的有效系统的使用将促进细胞和基因治疗包括基因组编辑的新策略的进一步发展。关键词离体扩增造血干细胞生态位信号转导脐带血移植SCID繁殖细胞基因组编辑CRISPR / Cas9。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号